Relmada Therapeutics (NASDAQ:RLMD) Shares Cross Below 50 Day Moving Average - What's Next?

Relmada Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Relmada shares fell below their 50-day moving average: The stock traded as low as $3.46 and last changed hands at $3.61, below its $3.75 50-day average and $5.33 200-day average.
  • Analyst views are mixed: MarketBeat reports a “Moderate Buy” consensus and an average $12 price target, while Weiss Ratings reaffirmed a “sell (D-)” rating.
  • The company reported a quarterly loss of $0.12 per share, slightly better than analysts’ $0.14 loss estimate. CFO Maged Shenouda also purchased 120,200 shares at an average $4.20 per share.
  • Five stocks to consider instead of Relmada Therapeutics.

Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $3.75 and traded as low as $3.46. Relmada Therapeutics shares last traded at $3.61, with a volume of 2,418,880 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Relmada Therapeutics in a research report on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Relmada Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $12.00.

Check Out Our Latest Stock Report on RLMD

Relmada Therapeutics Price Performance

The company has a fifty day moving average price of $3.75 and a 200 day moving average price of $5.33. The company has a market capitalization of $385.08 million, a P/E ratio of -5.01 and a beta of 0.62.

Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. On average, equities research analysts predict that Relmada Therapeutics, Inc. will post -0.62 earnings per share for the current fiscal year.

Insider Transactions at Relmada Therapeutics

In other news, CFO Maged Shenouda bought 120,200 shares of Relmada Therapeutics stock in a transaction on Wednesday, September 9th. The stock was purchased at an average cost of $4.20 per share, with a total value of $504,840.00. Following the purchase, the chief financial officer directly owned 920,200 shares of the company's stock, valued at approximately $3,864,840. This trade represents a 15.02% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 14.50% of the stock is owned by insiders.

Institutional Trading of Relmada Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its position in shares of Relmada Therapeutics by 14.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 880,889 shares of the company's stock worth $3,321,000 after buying an additional 113,265 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Relmada Therapeutics by 2,093.3% in the third quarter. Russell Investments Group Ltd. now owns 165,861 shares of the company's stock worth $625,000 after acquiring an additional 158,299 shares in the last quarter. Alps Advisors Inc. boosted its stake in Relmada Therapeutics by 31.8% in the 3rd quarter. Alps Advisors Inc. now owns 140,319 shares of the company's stock worth $529,000 after purchasing an additional 33,863 shares during the period. Profund Advisors LLC grew its holdings in shares of Relmada Therapeutics by 615.6% during the third quarter. Profund Advisors LLC now owns 195,555 shares of the company's stock valued at $737,000 after buying an additional 168,229 shares in the last quarter. Finally, AXQ Capital LP purchased a new position in Relmada Therapeutics during the 2nd quarter valued at about $84,000. Institutional investors own 45.24% of the company's stock.

Relmada Therapeutics Company Profile

(Get Free Report)

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing investigational treatments for central nervous system disorders, with a focus on depression. The company's work centers on advancing drug candidates through clinical research; it does not have an approved commercial product. Its best-known candidate, REL-1017 (esmethadone), is an oral compound that acts on NMDA receptors. Relmada has studied it as an add-on treatment for adults with major depressive disorder who have not responded adequately to existing antidepressants.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Relmada Therapeutics Right Now?

Before you consider Relmada Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relmada Therapeutics wasn't on the list.

While Relmada Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines